Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03442985 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Palovarotene for the Treatment of MO
A Phase 2 study, sponsored by Clementia Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 193
- Enrollment target
NCT03442985 is a Phase 2 study that was terminated before completion, run by Clementia Pharmaceuticals. The registered enrollment target is 193 participants.
The verdict
NCT03442985, a Phase 2 study, was terminated before completion, sponsored by Clementia Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 193 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study comparing the safety and efficacy of 2 dosage regimens of palovarotene versus placebo in preventing disease progression in pediatric subjects with multiple osteochondromas (MO).
Interventions
- OTHER Placebo
- DRUG Palovarotene 2.5 mg
- DRUG Palovarotene 5.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2018-03-22 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03442985
The ClinicalTrials.gov registry entry for NCT03442985 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clementia Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03442985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03442985 about?
NCT03442985 is a clinical study titled "An Efficacy and Safety Study of Palovarotene for the Treatment of MO". This is a randomized, double-blind, placebo-controlled study comparing the safety and efficacy of 2 dosage regimens of palovarotene versus placebo in preventing disease progression in pediatric subjects with multiple osteochondromas (MO).
What is the current status of trial NCT03442985?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 193 participants. The study started on 2018-03-22. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT03442985?
The interventions under investigation include: Placebo (OTHER), Palovarotene 2.5 mg (DRUG), Palovarotene 5.0 mg (DRUG).
Who is sponsoring clinical trial NCT03442985?
This trial is sponsored by Clementia Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.